List view / Grid view
A report has highlighted how the outsourcing of manufacturing activities to contract manufacturers is facilitating more streamlined and efficient pharmaceutical drug development.
Caroline Peachey chats with Mahesh Bhalgat, COO at Syngene International Limited about the role of new technology in biotherapeutics production.
3 May 2012 | By Abbott
Abbott plans to establish its first nutrition R&D center with Syngene...
6 September 2010 | By Syngene
Syngene, a world-leading manufacturer of image analysis sol- utions is delighted to introduce GENi, an affordable, fully motorised gel doc- umentation system...
4 March 2010 | By
Syngene, is pleased to announce its G:BOX EF gel documentation system is being used by scientists in a prestigious plant breeding centre at Aberystwyth University in Wales to help map the DNA and RNA from commercially important forage crops...
9 December 2009 | By
Syngene, is delighted to announce its GeneGnome dedicated chemiluminescent imaging system, has been used since 2003 to help successfully study the role of proteins in cell division...
26 November 2009 | By
Syngene, is delighted to announce that its Dyversity 2D imaging system is being used by one of Europe's leading research institutes, the University of Lausanne in Switzerland, to help identify proteins associated with neurodegenerative diseases...
29 September 2009 | By
Syngene, is pleased to announce that one of the USA’s foremost Medical Research Centers, the Albert Einstein College of Medicine in New York is using Dyversity, Syngene’s 2D gel imaging system...
29 September 2009 | By
Syngene, is pleased to announce the first ChromaScan automated non-radioactive TLC plate reader is being used in the main manufacturing facility of a major pharmaceutical company, to improve the accuracy of its drug testing...
Syngene, a world-leading manufacturer of image analysis solutions, is proud to announce its G:BOX chemiluminescence imaging system is being used by scientists at one of Scotland’s top Universities, Edinburgh Napier University in Edinburgh to accurately determine the effectiveness of novel anti-cancer therapies.
